CherubiniV, BonfantiR, CasertanoA, et al.Time in range in children with type 1 diabetes using treatment strategies based on nonautomated insulin delivery systems in the real world. Diabetes Technol Ther, 2020; 22(7):509–515.
2.
NørgaardK, RanjanAG, LaugesenC, et al.Glucose monitoring metrics in individuals with type 1 diabetes using different treatment modalities: A real-world observational study. Diabetes Care, 2023; 46(11):1958-–1964.
3.
RabboneI, SavastioS, PigniatielloC, et al.Significant and persistent improvements in time in range and positive emotions in children and adolescents with type 1 diabetes using a close-loop control system after attending a virtual educational camp. Acta Diabetol, 2022; 59(6):837–842.
4.
ArrietaA, BattelinoT, ScaramuzzaAE, et al.Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. Diabetes Obes Metab, 2022; 24(7):1370–1379.
5.
DovcK, LanzingerS, Cardona-HernandezR, et al.Association of achieving time in range clinical targets with treatment modality among youths with type 1 diabetes. JAMA Netw Open, 2023; 6(2):e230077.
6.
ScaramuzzaAE, CherubiniV, RabboneI. Open-source automated insulin delivery in type 1 diabetes. N Engl J Med, 202224; 387(21):2006–2007.
